chr3-196654609-G-A

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting

The NM_198565.3(NRROS):​c.70G>A​(p.Gly24Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000715 in 1,613,992 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.00060 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00073 ( 0 hom. )

Consequence

NRROS
NM_198565.3 missense

Scores

18

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:3

Conservation

PhyloP100: 1.74
Variant links:
Genes affected
NRROS (HGNC:24613): (negative regulator of reactive oxygen species) Enables transforming growth factor beta binding activity. Predicted to be involved in several processes, including microglia development; sequestering of TGFbeta in extracellular matrix; and transforming growth factor beta1 activation. Located in cell surface. [provided by Alliance of Genome Resources, Apr 2022]
PIGX (HGNC:26046): (phosphatidylinositol glycan anchor biosynthesis class X) This gene encodes a type I transmembrane protein in the endoplasmic reticulum (ER). The protein is an essential component of glycosylphosphatidylinositol-mannosyltransferase I, which transfers the first of the four mannoses in the GPI-anchor precursors during GPI-anchor biosynthesis. Studies in rat indicate that the protein is translated from a non-AUG translation initiation site. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.018257618).
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000604 (92/152306) while in subpopulation NFE AF= 0.00103 (70/68026). AF 95% confidence interval is 0.000835. There are 0 homozygotes in gnomad4. There are 45 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
NRROSNM_198565.3 linkuse as main transcriptc.70G>A p.Gly24Arg missense_variant 2/3 ENST00000328557.5

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
NRROSENST00000328557.5 linkuse as main transcriptc.70G>A p.Gly24Arg missense_variant 2/31 NM_198565.3 P1
PIGXENST00000426755.5 linkuse as main transcriptc.-50G>A 5_prime_UTR_variant 2/63
NRROSENST00000461791.1 linkuse as main transcriptn.202G>A non_coding_transcript_exon_variant 2/22

Frequencies

GnomAD3 genomes
AF:
0.000605
AC:
92
AN:
152188
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000590
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00103
Gnomad OTH
AF:
0.00144
GnomAD3 exomes
AF:
0.000458
AC:
115
AN:
251306
Hom.:
0
AF XY:
0.000464
AC XY:
63
AN XY:
135834
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000607
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000272
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000462
Gnomad NFE exome
AF:
0.000739
Gnomad OTH exome
AF:
0.000652
GnomAD4 exome
AF:
0.000727
AC:
1062
AN:
1461686
Hom.:
0
Cov.:
30
AF XY:
0.000682
AC XY:
496
AN XY:
727158
show subpopulations
Gnomad4 AFR exome
AF:
0.0000896
Gnomad4 AMR exome
AF:
0.000604
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.0000562
Gnomad4 NFE exome
AF:
0.000892
Gnomad4 OTH exome
AF:
0.000580
GnomAD4 genome
AF:
0.000604
AC:
92
AN:
152306
Hom.:
0
Cov.:
32
AF XY:
0.000604
AC XY:
45
AN XY:
74480
show subpopulations
Gnomad4 AFR
AF:
0.000241
Gnomad4 AMR
AF:
0.000589
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00103
Gnomad4 OTH
AF:
0.00142
Alfa
AF:
0.000831
Hom.:
0
Bravo
AF:
0.000612
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000778
AC:
3
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.00105
AC:
9
ExAC
AF:
0.000428
AC:
52
EpiCase
AF:
0.000927
EpiControl
AF:
0.000652

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsDec 13, 2023The c.70G>A (p.G24R) alteration is located in exon 2 (coding exon 1) of the NRROS gene. This alteration results from a G to A substitution at nucleotide position 70, causing the glycine (G) at amino acid position 24 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingInvitaeJun 11, 2022This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 24 of the NRROS protein (p.Gly24Arg). This variant is present in population databases (rs151257083, gnomAD 0.08%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with NRROS-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The arginine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Seizures, early-onset, with neurodegeneration and brain calcifications Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingRevvity Omics, RevvityAug 24, 2022- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Benign
-0.47
T
BayesDel_noAF
Benign
-0.51
CADD
Benign
15
DANN
Benign
0.90
DEOGEN2
Benign
0.055
T
Eigen
Benign
-0.40
Eigen_PC
Benign
-0.39
FATHMM_MKL
Benign
0.46
N
LIST_S2
Benign
0.63
T
M_CAP
Benign
0.010
T
MetaRNN
Benign
0.018
T
MetaSVM
Benign
-0.98
T
MutationTaster
Benign
1.0
N
PrimateAI
Benign
0.33
T
PROVEAN
Benign
-1.5
N
REVEL
Benign
0.060
Sift
Benign
0.092
T
Sift4G
Benign
0.12
T
Polyphen
0.14
B
Vest4
0.20
MutPred
0.53
Gain of MoRF binding (P = 0.0049);
MVP
0.35
MPC
0.47
ClinPred
0.029
T
GERP RS
3.7
Varity_R
0.071
gMVP
0.58

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs151257083; hg19: chr3-196381480; API